illumina inc american biotechnology company headquartered san diego california serves incorporated april illumina develops manufactures markets integrated systems analysis genetic variation biological function company provides line products services serves sequencing genotyping gene expression proteomics markets illuminas customers include genomic research centers pharmaceutical companies academic institutions clinical research organizations biotechnology illumina founded april david walt larry bock john stuelpnagel anthony czarnik mark chee working cw group venturecapital firm bock stuelpnagel uncovered would become illuminas beadarray tufts university negotiated exclusive license technology illumina acquired spyder instruments founded michal lebl richard houghten jutta eichler technology highthroughput synthesis oligonucleotides illumina completed initial public offering july illumina began offering single nucleotide polymorphism snp genotyping services launched first system illumina beadlab using goldengate genotyping technology illumina currently offers microarraybased products services expanding range genetic analysis sequencing including snp genotyping gene expression protein analysis illuminas technologies used broad range academic government pharmaceutical biotechnology leading institutions around globe january company completed acquisition british company solexa inc solexa founded june shankar balasubramanian david klenerman develop commercialize genomesequencing technology invented founders university cambridge solexa inc formed solexa ltd reversed lynx therapeutics illumina also uses dna colony sequencing technology invented pascal mayer laurent farinelli acquired solexa manteia predictive medicine used perform range analyses including whole genome resequencing geneexpression analysis small ribonucleic acid srna analysis june illumina announced launch personal full genome sequencing service depth illumina sold instruments labeled research use early illumina obtained fda approval beadxpress system used clinical part companys strategy time open clia lab begin offering clinical genetic testing illumina acquired epicentre biotechnologies based madison wisconsin january january hoffmannla roche made unsolicited bid buy illumina per share roche tried tactics including raising offer illumina rejected roche abandoned offer company announced multimilliondollar product hiseq x january illumina already held market genomesequencing illumina machines accounted dna data company invested acquisition precommercial firm enancio developed dna data compression algorithm specifically targeting illumina data capable reducing storage footprint eg gb compressed july jay flatley ceo since assumed role executive chairman board directors francis desouza president company since took additional role late illumina spun company grail focused blood testing cancer tumors bloodstream grail planned raise billion second round financing received funding bill gates jeff bezos investing million series funding illumina maintaining holding share grail working blood test trial women scheduled mammogram visits states minnesota wisconsin well partnership mayo clinic grail uses illumina sequencing technology grail planned roll tests september illumina announced proposed cash stock deal acquire grail november illumina proposed acquisition pacific biosciences per share around billion december federal trade commission ftc sued block proposed deal abandoned january illumina paying pacific million termination march ftc sued block illuminas billion vertical merger july european commission opened indepth investigation grail acquisition orders active investigations us ftc eu european commission illumina publicly announced completed acquisition grail august ftc urged illumina unwind merger shortly october european commission ordered illumina keep grail separate adopted interim measures prevent harm competition face penalty payments average daily turnover andor fines annual worldwide turnover articles eu merger regulation september us administrative judge ruled ftcs efforts prevent acquisition antitrust april ftc ordered grail divested july european commission imposed million million penalty illumina closing grail acquisition without eu september illumina launched novaseq x novaseq x novaseq x plus sequence genomes per year compared per year illuminas previous machines generate tb data per series includes redeveloped reagents dyes polymerases shipped ambient june desouza resigned ceo illumina replaced interim ceo charles dadswell companys general also june hologic ceo stephen macmillan named nonexecutive chairman board september agilent technologies senior vice president jacob thaysen appointed october european commission ordered grail divested illumina within next twelve illumina said would explore thirdparty sale capital markets transaction fails win ongoing challenge following illustration companys mergers acquisitions spinoffs historical predecessors illumina sells number highthroughput dna sequencing systems also known dna sequencers based technology developed solexa technology features bridge amplification generate clusters reversible terminators sequence technology behind sequencing systems involves ligation fragmented dna chip followed primer addition sequential fluorescent dntp incorporation detection depending kit used according company miseq series generates million reads per dual flow cells nextseq generates billion single reads per novaseq x series generates billion single reads per illumina uses nextgeneration sequencing far faster efficient traditional sanger illumina sequencers perform shortread sequencing image based utilizing illumina dye technology higher accuracy longread illumina sequencing happens within flow cells flow cells small size housed flow cell compartment flow cell clustering happens denatured dna sample placed flow cell primers already flow cell channel capture bind ends short denatured dna sample dna polymerase added dna building blocks introduced results newly synthesized strand constrained bottom flow cell next original template strand washed binding newly synthesized strand dna sequence present surface dna polymerase building blocks introduced forming new strand steps repeated copies made cofounder former chief scientific officer anthony czarnik sued illumina case czarnik v illumina inc trial court granted illuminas motion dismiss part allowed czarniks correction inventorship claims cornell university life technologies filed lawsuit illumina alleging microarray products infringed eight patents held university exclusively licensed startup case settled april without finding fault september parties asked settlement reviewed cornell accusing illumina life technologies misrepresentation cornell claimed thermofisher promised settle suit illumina asked markman wording dropped could file subsequent suit involving patents invented cornell instead filing suit thermofisher illumina settled another lawsuit california secretly sublicensed patents dr monib zirvi filed lawsuit southern district new york illumina key employees claiming knowingly incorporated ideas zipcode dna sequences invented barany lab illuminas patent applications although suit dismissed illumina attorneys claimed ip misappropriation storm warnings thus statutes limitations run particular claims dr monib zirvi also filed foia case new jersey unredacted copies key nih grants illumina filed early existence william noon inhouse attorney illumina filed foia request key grants well january illumina party patent lawsuit competitor ariosa diagnostics litigation began verinata health filing suit ariosa illumina joined suit acquiring verinata ariosa subsequently brought counterclaim trial court granted summary judgment favor ariosa united states court appeals federal circuit ariosa initially pursued appeal supreme court united states two parties resolved dispute court decided whether take february illumina filed lawsuit oxford nanopore technologies illumina claimed oxford nanopore infringed patents use biological nanopore mycobacterium smegmatis porina mspa sequencing august parties settled february illumina filed patent infringement suit bgi relating coolmps sequencing return bgi filed patent infringement lawsuits violation federal antitrust california unfair competition laws claiming use fraudulent behavior obtain enforce sequencing patents asserted bgi preventing firm entering us however may illumina ordered pay million us unit bgi california infringing two patents dnasequencing systems jury case also said illumina willfully infringed patents former accusation bgis infringement may jury us district court district delaware rendered verdict illumina willfully infringed two patents owned complete genomics awarded approximately million cgi past damages jury also invalidated three patents owned march illumina sued helmy eltoukhy amir talasaz cofounders guardant stealing trade guardant called lawsuit frivolous retaliatory framed response concerns illuminagrail guardant also claimed lawsuit filed order suppress competition